Cipla Lanreotide Injection 120 mg recalled for particulate matter
Cipla USA is recalling certain pre-filled syringes of Lanreotide Injection 120 mg because they may contain particulate matter (small particles) in the solution. The affected syringes have specific lot numbers and expiration dates between October 2026 and March 2027. No injuries have been reported so far.
From the FDA notice · Read the official notice ↗ · All Cipla recalls
What to do
- Check if you have Lanreotide Injection with one of the recalled lot numbers listed in the FDA notice.
- Do not use the affected syringes.
- Contact your pharmacy or healthcare provider for a replacement or alternative medication.
- Keep the syringe and lot number information when you contact your provider.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- 15,221 syringes
- Illnesses reported
- None reported
- Manufactured in
- 10 Independence Blvd, Warren, NJ, United States
- Classification
- Class II
- Recall number
- D-0290-2026
In the FDA's words
- Description
- Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67 Presence of Particulate Matter. Lot, expiry: 4301954IR1 , exp 31/10/2026 ; 4301994IR1 , exp 31/10/2026 ; 4301995IR1 , exp 31/10/2026 ; 4301996IR1 , exp 31/10/2026 ; 4400005IR1 , exp 30/11/2026 ; 4400006IR1 , exp 30/11/2026 ; 4400007IR1 , exp 30/11/2026 ; 4400124IR1 , exp 30/11/2026 ; 4400154IR1 , exp 30/11/2026 ; 4400155IR1 , exp 30/11/2026 ; 4400156IR1 , exp 30/11/2026 ; 4400373IR1 , exp 31/12/2026 ; 4400374IR1 , exp 31/12/2026 ; 4400375IR1 , exp 31/12/2026 ; 4400455IR1 , exp 31/1/2027 ; 4400456IR1 , exp 31/1/2027 ; 4400457IR1 , exp 31/1/2027 ; 4400544IR1 , exp 28/2/2027 ; 4400606IR1 , exp 28/2/2027 ; 4400607IR1 , exp 28/2/2027 ; 4400696IR1 , exp 28/2/2027 ; 4400697IR1 , exp 28/2/2027 ; 4400779IR1 , exp 28/2/2027 ; 4400780IR1 , exp 28/2/2027 ; 4400781IR1 , exp 28/2/2027 ; 4400844IR1 , exp 31/3/2027 ; 4400845IR1 , exp 31/3/2027 ; 4400849IR1 , exp 31/3/2027 ; 4400984IR1 , exp 31/3/2027 ; 4400985RIR , exp 31/3/2027 ; 4400986IR1 , exp 31/3/2027 ; 4401023IR1 , exp 31/3/2027 ; Distribution: Nationwide in the USA Affected quantity: 15,221 syringes
- Hazard
- Presence of Particulate Matter.
More from Cipla
See all- Cipla USA fosfomycin granules recalled for failed impurity specs
ModerateFDAOct 14, 2026